Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors

Brain Research

Volumn 1314, Issue , 2010, Pages 206-218

  Picciotto, Marina R ^a   Brabant, Christian ^a,b   Einstein, Emily B ^a   Kamens, Helen M ^a   Neugebauer, Nichole M ^a  

^a Yale University School of Medicine   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Addiction; Dorsal raphe; Drug abuse; Galanin; HPA axis; Locus coeruleus; Mesolimbic dopamine system; Opiate withdrawal; Opiates; Psychostimulant; Stress

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CYCLIC AMP; DOPAMINE; GALANIN; GALANIN RECEPTOR; MORPHINE; NORADRENALIN; POTASSIUM CHANNEL;

ADDICTION; ANXIETY; BIOLOGICAL ACTIVITY; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG EXPOSURE; DRUG WITHDRAWAL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MONOAMINERGIC SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRESS;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; GALANIN; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LIMBIC SYSTEM; RECEPTORS, GALANIN; STRESS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 75149198307     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.08.033     Document Type: Review

References (132)

1. Aghajanian G.K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 276 (1978) 186-188
2. Ahren B., Berggren P.O., Bokvist K., and Rorsman P. Does galanin inhibit insulin secretion by opening of the ATP-regulated K+ channel in the beta-cell?. Peptides 10 (1989) 453-457
3. Antoniou K., Kehr J., Snitt K., and Ögren S.O. Differential effects of the neuropeptide galanin on striatal acetylcholine release in anaesthetized and awake rats. Br. J. Pharmacol. 121 (1997) 1180-1186
4. Aston-Jones G., Delfs J.M., Druhan J., and Zhu Y. The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. Ann. N.Y. Acad. Sci. 877 (1999) 486-498
5. Badie-Mahdavi H., Lu X., Behrens M., and Bartfai T. Role of galanin receptor 1 and galanin receptor 2 activation in synaptic plasticity associated with 3′, 5′-cyclic amp response element-binding protein phosphorylation in the dentate gyrus: studies with a galanin receptor 2 agonist and galanin receptor 1 knockout mice. Neuroscience 133 (2005) 591-604
6. Barr A., Kinney J., Hill M., Lu X., Biros S., Rebek J., and Bartfai T. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci. Lett. 405 (2006) 111-115
7. Bartfai T., Iverfeldt K., Fisone G., and Serfozo P. Regulation of the release of coexisting neurotransmitters. Annu. Rev. Pharmacol. Toxicol. 28 (1988) 285-310
8. Bauer J.W., Lang R., Jakab M., and Kofler B. Galanin family of peptides in skin function. Cell. Mol. Life Sci. 65 (2008) 1820-1825
9. Befort K., Filliol D., Ghate A., Darcq E., Matifas A., Muller J., Lardenois A., Thibault C., Dembele D., Merrer J.L., Becker J.A.J., Poch O., and Kieffer B.L. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur. J. Neurosci. 27 (2008) 2973-2984
10. Belfer I., Hipp H., Bollettino A., McKnight C., Evans C., Virkkunen M., Albaugh B., Max M.B., Goldman D., and Enoch M.A. Alcoholism is associated with GALR3 but not two other galanin receptor genes. Genes Brain Behav. 6 (2007) 473-481
11. Belfer I., Hipp H., McKnight C., Evans C., Buzas B., Bollettino A., Albaugh B., Virkkunen M., Yuan Q., Max M.B., Goldman D., and Enoch M.A. Association of galanin haplotypes with alcoholism and anxiety in two ethnically distinct populations. Mol. Psychiatry 11 (2006) 301-311
12. Bellido I., Diaz-Cabiale Z., Jimenez-Vasquez P.A., Andbjer B., Mathe A.A., and Fuxe K. Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci. Lett. 317 (2002) 101-105
13. Bonsi P., Cuomo D., Ding J., Sciamanna G., Ulrich S., Tscherter A., Bernardi G., Surmeier D.J., and Pisani A. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 32 (2007) 1840-1854
14. Burgevin M.C., Loquet I., Quarteronet D., and Habert-Ortoli E. Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J. Mol. Neurosci. 6 (1995) 33-41
15. Carlezon W.A.J., and Thomas M.J. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 56 (2009) 122-132
16. Consolo S., Baldi G., Russi G., Civenni G., Bartfai T., and Vezzani A. Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. Proc. Natl. Acad. Sci. USA 91 (1994) 8047-8051
17. Coumis U., and Davies C.H. The effects of galanin on long-term synaptic plasticity in the CA1 area of rodent hippocampus. Neuroscience 112 (2002) 173-182
18. Counts S.E., McGuire S.O., Sortwell C.E., Crawley J.N., Collier T.J., and Mufson E.J. Galanin inhibits tyrosine hydroxylase expression in midbrain dopaminergic neurons. J. Neurochem. 83 (2002) 442-451
19. Counts S.E., Perez S.E., and Mufson E.J. Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?. Cell. Mol. Life Sci. 65 (2008) 1842-1853
20. Crawley J.N. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. Cell. Mol. Life Sci. 65 (2008) 1836-1841
21. Di Matteo V., Di Giovanni G., Pierucci M., and Esposito E. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog. Brain Res. 172 (2008) 7-44
22. Dong Y., Tyszkiewicz J., and Fong T. Galanin and galanin-like peptide differentially modulate neuronal activities in rat arcuate nucleus neurons. J. Neurophysiol. 95 (2006) 3228-3234
23. Elhamdani A., Martin T.F., Kowalchyk J.A., and Artalejo C.R. Ca(2+)-dependent activator protein for secretion is critical for the fusion of dense-core vesicles with the membrane in calf adrenal chromaffin cells. J. Neurosci. 19 (1999) 7375-7383
24. Ellis Y., and Davies J.A. The effect of neuropeptides on the release of neurotransmitter amino acids from rat striatum. Neuropeptides 26 (1994) 65-69
25. Ericson E., and Ahlenius S. Suggestive evidence for inhibitory effects of galanin on mesolimbic dopaminergic neurotransmission. Brain Res. 822 (1999) 200-209
26. File S.E., Kenny P.J., and Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol. Biochem. Behav. 66 (2000) 65-72
27. Fisone G., Wu C.F., Consolo S., Nordstrom O., Brynne N., Bartfai T., Melander T., and Hökfelt T. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc. Natl. Acad. Sci. USA 84 (1987) 7339-7343
28. Fuertes G., Laorden M.L., and Milanés M.V. Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology 71 (2000)
29. Fuxe K., Marcellino D., Rivera A., Diaz-Cabiale Z., Filip M., Gago B., Roberts D.C.S., Langel U., Genedani S., Ferraro L., de la Calle A., Narvaez J., Tanganelli S., Woods A., and Agnati L.F. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev. 58 (2008) 415-452
30. Grenhoff J., Nisell M., Ferre S., Aston-Jones G., and Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. 93 (1993) 11-25
31. Havel P.J., Mundinger T.O., Veith R.C., Dunning B.E., and Taborsky Jr. G.J. Corelease of galanin and NE from pancreatic sympathetic nerves during severe hypoglycemia in dogs. Am. J. Physiol. 263 (1992) E8-E16
32. Hawes J.J., and Picciotto M.R. Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain. J. Comp. Neurol. 479 (2004) 410-423
33. Hawes J.J., and Picciotto M.R. GalR1 and GalR2 antisera recognize bands in their respective knockout mice (erratum for JCN 479:410). J. Comp. Neurol. 490 (2005) 98-100
34. Hawes J.J., Brunzell D.H., Narasimhaiah R., Langel U., Wynick D., and Picciotto M.R. Galanin protects against behavioral and neurochemical correlates of opiate reward. Neuropsychopharmacology 33 (2008) 1864-1873
35. Hawes J.J., Brunzell D.H., Wynick D., Zachariou V., and Picciotto M.R. GalR1, but not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a cyclic AMP-dependent mechanism. J. Neurochem. 93 (2005) 1168-1176
36. Hawes J.J., Narasimhaiah R., and Picciotto M.R. Galanin and galanin-related peptide modulate neurite outgrowth via PKC-mediated activation of ERK. Eur. J. Neurosci. 23 (2006) 2937-2946
37. Hawes J.J., Narasimhaiah R., and Picciotto M.R. Galanin attenuates cyclic AMP regulatory element-binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures. J. Neurochem. 96 (2006) 1160-1168
38. Hensler J. Serotonergic modulation of the limbic system. Neurosci. Biobehav. Rev. 30 (2006) 203-214
39. Hikida T., Kitabatake Y., Pastan I., and Nakanishi S. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc. Natl. Acad. Sci. USA 100 (2003) 6169-6173
40. Hobson S.A., Bacon A., Elliot-Hunt C.R., Holmes F.E., Kerr N.C.H., Pope R., Vanderplank P., and Wynick D. Galanin acts as a trophic factor to the central and peripheral nervous systems. Cell. Mol. Life Sci. 65 (2008) 1806-1812
41. Hokfelt T., and Tatemoto K. Galanin-25 years with a multitalented neuropeptide. Cell. Mol. Life Sci. 65 (2008) 1793-1795
42. Holmes A., Kinney J.W., Wrenn C.C., Li Q., Yang R.J., Ma L., Vishwanath J., Saavedra M.C., Innerfield C.E., Jacoby A.S., Shine J., Iismaa T.P., and Crawley J.N. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Neuropsychopharmacology 28 (2003) 1031-1044
43. Holmes A., and Picciotto M.R. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?. CNS Neurol. Disord. Drug Targets 5 (2006) 225-232
44. Hooi S.C., Maiter D.M., Martin J.B., and Koenig J.I. Galaninergic mechanisms are involved in the regulation of corticotropin and thyrotropin secretion in the rat. Endocrinology (1990) 2281-2289
45. Hyde J.F., and Keller B.K. Galanin secretion from anterior pituitary cells in vitro is regulated by dopamine, somatostatin, and thyrotropin-releasing hormone. Endocrinology 128 (1991) 917-922
46. Jacobowitz D.M., Kresse A., Skofitsch G., Jacobowitz D.M., Kresse A., and Skofitsch G. Galanin in the brain: chemoarchitectonics and brain cartography-a historical review. Peptides 25 (2004) 433-464
47. Janowsky D.S., and Overstreet D.H. Cholinergic dysfunction in depression. Pharmacol. Toxicol. 3 (1990) 100-111
48. Karlsson R., and Holmes A. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 31 (2006) 231-239
49. Kehr J., Yoshitake T., Wang F., Wynick D., Holmberg K., Lendahl U., Bartfai T., Yamaguchi M., Hökfelt T., and Ögren S. Microdialysis in freely moving mice: determination of acetylcholine, serotonin and noradrenaline release in galanin transgenic mice. J. Neurosci. Methods 109 (2001) 71-80
50. Kinney G.A., Emmerson P.J., and Miller R.J. Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus. J. Neurosci. 18 (1998) 3489-3500
51. Kolakowski Jr. L.F., O'Neill G.P., Howard A.D., Broussard S.R., Sullivan K.A., Feighner S.D., Sawzdargo M., Nguyen T., Kargman S., Shiao L.L., Hreniuk D.L., Tan C.P., Evans J., Abramovitz M., Chateauneuf A., Coulombe N., Ng G., Johnson M.P., Tharian A., Khoshbouei H., George S.R., Smith R.G., and O'Dowd B.F. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J. Neurochem. 71 (1998) 2239-2251
52. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13 (1992) 177-184
53. Koob G.F. A role for brain stress systems in addiction. Neuron 59 (2008) 11-34
54. Koob G.F. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 (2009) 18-31
55. Koob G.F., Maldonado R., and Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci. 15 (1992) 186-191
56. Kozoriz M.G., Kuzmiski J.B., Hirasawa M., and Pittman Q.J. Galanin modulates neuronal and synaptic properties in the rat supraoptic nucleus in a use and state dependent manner. J. Neurophysiol. 96 (2006) 154-164
57. Kreek M.J., Schlussman S.D., Reed B., Zhang Y., Nielsen D.A., Levran O., Zhou Y., and Butelman E.R. Bidirectional translational research: progress in understanding addictive diseases. Neuropharmacology 56 (2009) 32-43
58. Kuteeva E., Hokfelt T., and Ogren S.O. Behavioural characterisation of transgenic mice overexpressing galanin under the PDGF-B promoter. Neuropeptides 39 (2005) 299-304
59. Kuteeva E., Hökfelt T., and Ögren S.O. Behavioural characterisation of young adult transgenic mice overexpressing galanin under the PDGF-B promoter. Regulatory Pept. 125 (2005) 67-78
60. Kuteeva E., Hokfelt T., Wardi T., and Ogren S.O. Galanin, galanin receptor subtypes and depression-like behaviour. Cell. Mol. Life Sci. 65 (2008) 1854-1863
61. Kyrkouli S.E., Stanley B.G., and Leibowitz S.F. Galanin: stimulation of feeding induced by medial hypothalamic injection of this novel peptide. Eur. J. Pharmacol. 122 (1986) 159-160
62. Lang R., Gundlach A.L., and Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 115 (2007) 177-207
63. Leibowitz S.F., Avena N.M., Chang G.-Q., Karatayev O., Chau D.T., and Hoebel B.G. Ethanol intake increases galanin mRNA in the hypothalamus and withdrawal decreases it. Physiol. Behav. 79 (2003) 103-111
64. Lerner J.T., Sankar R., and Mazarati A.M. Galanin and epilepsy. Cell. Mol. Life Sci. 65 (2008) 1864-1871
65. Levin M.C., Sawchenko P.E., Howe P.R., Bloom S.R., and Polak J.M. Organization of galanin-immunoreactive inputs to the paraventricular nucleus with special reference to their relationship to catecholaminergic afferents. J. Comp. Neurol. 261 (1987) 562-582
66. Levran O., Londono D., O'Hara K., Nielsen D.A., Peles E., Rotrosen J., Casadonte P., Linzy S., Randesi M., Ott J., Adelson M., and Kreek M.J. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 7 (2008) 720-729
67. Lewis M.J., Johnson D.F., Waldman D., Leibowitz S.F., and Hoebel B.G. Galanin microinjection in the third ventricle increases voluntary ethanol intake. Alcohol., Clin. Exp. Res. 28 (2004) 1822-1828
68. Lu X., and Bartfai T. Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 379 (2009) 417-420
69. Lukkes J.L., Forster G.L., Renner K.J., and Summers C.H. Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur. J. Pharmacol. 578 (2008) 185-193
70. Ma X., Tong Y.G., Schmidt R., Brown W., Payza K., Hodzic L., Pou C., Godbout C., Hokfelt T., and Xu Z.Q. Effects of galanin receptor agonists on locus coeruleus neurons. Brain Res. 919 (2001) 169-174
71. Mahoney S.-A., Hosking R., Farrant S., Holmes F.E., Jacoby A.S., Shine J., Iismaa T.P., Scott M.K., Schmidt R., and Wynick D. The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J. Neurosci. 23 (2003) 416-421
72. Maldonado R., and Koob G.F. Destruction of the locus coeruleus decreases physical signs of opiate withdrawal. Brain Res. 605 (1993) 128-138
73. Mazarati A.M., Hohmann J.G., Bacon A., Liu H., Sankar R., Steiner R.A., Wynick D., and Wasterlain C.G. Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 20 (2000) 6276-6281
74. McBride W.J., Murphy J.M., and Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav. Brain Res. 101 (1999) 129-152
75. Mechenthaler I. Galanin and the neuroendocrine axes. Cell. Mol. Life Sci. 65 (2008) 1826-1835
76. Melander T., Hökfelt T., Rokaeus A., Cuello A.C., Oertel W.H., Verhofstad A., and Goldstein M. Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J. Neurosci. 6 (1986) 3640-3654
77. Mitsukawa K., Lu X., and Bartfai T. Galanin, galanin receptors and drug targets. Cell. Mol. Life Sci. 65 (2008) 1796-1805
78. Mitsukawa K., Lu X., and Bartfai T. Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1. Neuroscience 160 (2009) 837-846
79. Morilak D.A., Barrera G., Echevarria D.J., Garcia A.S., Hernandez A., Ma S., and Petre C.O. Role of brain norepinephrine in the behavioral response to stress. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 1214-1224
80. Narasimhaiah R., Kamens H., and Picciotto M. Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice. Psychopharmacology 204 (2009) 95-102
81. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59 (2006) 1151-1159
82. Nishibori M., Oishi R., Itoh Y., and Saeki K. Galanin inhibits noradrenaline-induced accumulation of cyclic AMP in the rat cerebral cortex. J. Neurochem. 51 (1988) 1953-1955
83. Nunez C., Foldes A., Laorden M.L., Milanes M.V., and Kovacs K.J. Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J. Neurochem. 101 (2007) 1060-1071
84. Nunez C., Laorden M.L., and Milanes M.V. Regulation of serine (Ser)-31 and Ser40 tyrosine hydroxylase phosphorylation during morphine withdrawal in the hypothalamic paraventricular nucleus and nucleus tractus solitarius-A2 cell group: role of ERK1/2. Endocrinology 148 (2007) 5780-5793
85. O'Donnell D., Ahmad S., Wahlestedt C., and Walker P. Expression of the novel galanin receptor subtype GALR2 in the adult rat CNS: distinct distribution from GALR1. J. Comp. Neurol. 409 (1999) 469-481
86. Ögren S.O., Pramanik A., Land T., and Langel Ü. Differential effects of the putative galanin receptor antagonists M15 and M35 on striatal acetylcholine release. Eur. J. Pharmacol. 242 (1993) 59-64
87. Ögren S.O., Schott P.A., Kehr J., Misane I., and Razani H. Galanin and learning. Brain Res. 848 (1999) 174-182
88. Olson V.G., Heusner C.L., Bland R.J., During M.J., Weinshenker D., and Palmiter R.D. Role of noradrenergic signaling by the nucleus tractus solitarius in mediating opiate reward. Science 311 (2006) 1017-1020
89. Owens M.J., and Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43 (1991) 425-473
90. Papas S., and Bourque C.W. Galanin inhibits continuous and phasic firing in rat hypothalamic magnocellular neurosecretory cells. J. Neurosci. 17 (1997) 6048-6056
91. Parker E.M., Izzarelli D.G., Nowak H.P., Mahle C.D., Iben L.G., Wang J., and Goldstein M.E. Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells. Mol. Brain Res. 34 (1995) 179-189
92. Pieribone V.A., Xu Z.Q., Zhang X., Grillner S., Bartfai T., and Hökfelt T. Galanin induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the brainstem slice. Neuroscience 64 (1995) 861-874
93. Poulain P., Decrocq N., and Mitchell V. Direct inhibitory action of galanin on hypothalamic arcuate nucleus neurones expressing galanin receptor Gal-R1 mRNA. Neuroendocrinology 78 (2003) 105-117
94. Quinn J.G., O'Hare E., Levine A.S., and Kim E.M. Evidence for a mu-opioid-opioid connection between the paraventricular nucleus and ventral tegmental area in the rat. Brain Res. 991 (2003) 206-211
95. Rada P., Avena N.M., Leibowitz S.F., and Hoebel B.G. Ethanol intake is increased by injection of galanin in the paraventricular nucleus and reduced by a galanin antagonist. Alcohol 33 (2004) 91-97
96. Rada P., Mark G.P., and Hoebel B.G. Galanin in the hypothalamus raises dopamine and lowers acetylcholine release in the nucleus accumbens: a possible mechanism for hypothalamic initiation of feeding behavior. Brain Res. 798 (1998) 1-6
97. Rasmussen K., Beitner-Johnson D.B., Krystal J.H., Aghajanian G.K., and Nestler E.J. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J. Neurosci. 10 (1990) 2308-2317
98. Robinson J., and Brewer A. Galanin: a potential role in mesolimbic dopamine-mediated instrumental behavior. Neurosci. Biobehav. Rev. 32 (2008) 1485-1493
99. Rodaros D., Caruana D.A., Amir S., and Stewart J. Corticotropin-releasing factor projections from limbic forebrain and paraventricular nucleus of the hypothalamus to the region of the ventral tegmental area. Neuroscience 150 (2007) 8-13
100. Sakurai E., Maeda T., Kaneko S., Akaike A., and Satoh M. Galanin inhibits long-term potentiation at Schaffer collateral-CA1 synapses in guinea-pig hippocampal slices. Neurosci. Lett. 212 (1996) 21-24
101. Sawchenko P.E., and Swanson L.W. Central noradrenergic pathways for the integration of hypothalamic neuroendocrine and autonomic responses. Science 214 (1981) 685-687
102. Schneider E.R., Rada P., Darby R.D., Leibowitz S.F., and Hoebel B.G. Orexigenic peptides and alcohol intake: differential effects of orexin, galanin, and ghrelin. Alcohol., Clin. Exp. Res. 31 (2007) 1858-1865
103. Seutin V., Verbanck P., Massotte L., and Dresse A. Galanin decreases the activity of locus coeruleus neurons in vitro. Eur. J. Pharmacol. 164 (1989) 373-376
104. Sevcik J., Finta E.P., and Illes P. Galanin receptors inhibit the spontaneous firing of locus coeruleus neurones and interact with mu-opioid receptors. Eur. J. Pharmacol. 230 (1993) 223-230
105. Seward E.P., Chernevskaya N.I., and Nowycky M.C. Exocytosis in peptidergic nerve terminals exhibits two calcium-sensitive phases during pulsatile calcium entry. J. Neurosci. 15 (1995) 3390-3399
106. Sharkey L., Madamba S., Siggins G., and Bartfai T. Galanin alters GABAergic neurotransmission in the dorsal raphe nucleus. Neurochem. Res. 33 (2007) 285-291
107. Smith S.M., and Vale W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin. Neurosci. 8 (2006) 383-395
108. Smith K.E., Walker M.W., Artymyshyn R., Bard J., Borowsky B., Tamm J.A., Yao W.J., Vaysse P.J., Branchek T.A., Gerald C., and Jones K.A. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J. Biol. Chem. 273 (1998) 23321-23326
109. Stone E.A., Lin Y., and Quartermain D. A final common pathway for depression? Progress toward a general conceptual framework. Neurosci. Biobehav. Rev. 32 (2008) 508-524
110. Swanson C., Blackburn T., Zhang X., Zheng K., Xu Z., Hokfelt T., Wolinsky T., Konkel M., Chen H., Zhong H., Walker M., Craig D., Gerald C., and Branchek T. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc. Natl. Acad. Sci. USA 102 (2005) 17489-17494
111. Tatemoto K., Rokaeus A., Jornvall H., McDonald T.J., and Mutt V. Galanin-a novel biologically active peptide from porcine intestine. FEBS Lett. 164 (1983) 124-128
112. Thomas P., Wong J.G., Lee A.K., and Almers W. A low affinity Ca2+ receptor controls the final steps in peptide secretion from pituitary melanotrophs. Neuron 11 (1993) 93-104
113. Tortorella C., Neri G., and Nussdorfer G. Galanin in the regulation of the hypothalamic-pituitary-adrenal axis. Int. J. Mol. Med. 19 (2007) 639-647
114. Tsuda K., Tsuda S., Nishio I., Masuyama Y., and Goldstein M. Effects of galanin on dopamine release in the central nervous system of normotensive and spontaneously hypertensive rats. Am. J. Hypertens. 11 (1998) 1475-1479
115. Tyszkiewicz J.P., Fong T.M., and Dong Y. GABAB receptors are required for galanin modulation of membrane properties of neurons in the arcuate nucleus of rats. Brain Res. 1191 (2008) 63-68
116. Van Bockstaele E.J., and Pickel V.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J. Comp. Neurol. 334 (1993) 603-617
117. Van Bockstaele E.J., Biswas A., and Pickel V.M. Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res. 624 (1993) 188-198
118. Wang S., Hashemi T., Fried S., Clemmons A.L., and Hawes B.E. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 37 (1998) 6711-6717
119. Wang S., Hashemi T., He C., Strader C., and Bayne M. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol. Pharmacol. 52 (1997) 337-343
120. Weiss J., Boss-Williams K., Moore J., Demetrikopoulos M., Ritchie J., and West C. Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. Neuropeptides 39 (2005) 279-285
121. Williams M.J., and Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 33 (2007) 1779-1797
122. Wise R. Opiate reward: sites and substrates. Neurosci. Biobehav. Rev. 13 (1989) 129-133
123. Xu Z.Q., Shi T.J., and Hökfelt T. Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J. Comp. Neurol. 392 (1998) 227-251
124. Xu Z.Q., Zhang X., Pieribone V.A., Grillner S., and Hökfelt T. Galanin-5-hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience 87 (1998) 79-94
125. Xu Z.Q., Tong Y.G., and Hokfelt T. Galanin enhances noradrenaline-induced outward current on locus coeruleus noradrenergic neurons. NeuroReport 12 (2001) 1779-1782
126. Xu X.-J., Hokfelt T., and Wiesenfeld-Hallin Z. Galanin and spinal pain mechanisms: where do we stand in 2008?. Cell. Mol. Life Sci. 65 (2008) 1813-1819
127. Yoshimoto K., and McBride W.J. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem. Res. 17 (1992) 401-407
128. Yoshitake T., Wang F., Kuteeva E., Holmberg K., Yamaguchi M., Crawley J., Steiner R., Bartfai T., Ogren S., Hokfelt T., and Kehr J. Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test. Proc. Natl. Acad. Sci. USA 101 (2004) 354-359
129. Zachariou V., Brunzell D.H., Hawes J., Stedman D.R., Bartfai T., Steiner R.A., Wynick D., Langel U., and Picciotto M.R. The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proc. Natl. Acad. Sci. USA 100 (2003) 9028-9033
130. Zachariou V., Georgescu D., Kansal L., Merriam P., and Picciotto M.R. Galanin receptor 1 gene expression is regulated by cyclic-AMP through a CREB-dependent mechanism. J. Neurochem. 76 (2001) 191-200
131. Zachariou V., Parikh K., and Picciotto M.R. Centrally administered galanin blocks morphine place preference in the mouse. Brain Res. 831 (1999) 33-42
132. Zachariou V., Thome J., Parikh K., and Picciotto M.R. Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Neuropsychopharmacology 23 (2000) 127-137